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Ubiquitin-like proteinsAbstract Ubiquitin-fold modifier 1 (UFM1) is one of the newly-identiﬁed ubiquitin-like proteins.
Similar to ubiquitin, UFM1 is conjugated to its target proteins by a three-step enzymatic reaction.
The UFM1-activating enzyme, ubiquitin-like modiﬁer-activating enzyme 5 (UBA5), serves as the
E1 to activate UFM1; UFM1-conjugating enzyme 1 (UFC1) acts as the E2 to transfer the activated
UFM1 to the active site of the E2; and the UFM1-speciﬁc ligase 1 (UFL1) acts as the E3 to recog-
nize its substrate, transfer, and ligate the UFM1 from E2 to the substrate. This process is called
ufmylation. UFM1 chains can be cleaved from its target proteins by UFM1-speciﬁc proteases
(UfSPs), suggesting that the ufmylation modiﬁcation is reversible. UFM1 cascade is conserved
among nearly all of the eukaryotic organisms, but not in yeast, and associated with several cellular
activities including the endoplasmic reticulum stress response and hematopoiesis. Furthermore, the
UFM1 cascade is closely related to a series of human diseases. In this review, we summarize the
molecular details of this reversible modiﬁcation process, the recent progress of its functional studies,
as well as its implication in tumorigenesis and potential therapeutic targets for cancer.Introduction
Protein post-translational modiﬁcations (PTM) refer to cova-
lent and generally enzymatic modiﬁcation of proteins during
or after protein biosynthesis. Up to now, more than 200 types
of PTMs have been reported, including addition of functional
groups (e.g., phosphorylation, methylation, and acetylation),conjugation of other proteins or peptides (e.g., ubiquitination),
chemical modiﬁcation of amino acid (AA) residues (e.g.,
deamidation), and structural changes (e.g., disulﬁde bridges)
[1,2]. A protein can be modiﬁed with one type of PTM or vari-
eties of combinations of PTM types. Moreover, one type of
PTM may contain one (e.g., phosphorylation), a few (e.g.,
methylation), and up to many (e.g., ubiquitination and
glycosylation) subtypes. Therefore, PTMs expand exponen-
tially cellular protein varieties and increase a cellular proteome
to more than one million different proteins to cope with the
complex and ﬁne-tuned cellular activities, such as protein–
protein interactions, cell cycle control, cell differentiation, gene
transcription, signal transduction, DNA damage repair,
apoptosis, endocytosis, and receptor trafﬁcking [3–5].nces and
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glycosylation and phosphorylation [6]. Ubiquitin (Ub) is con-
jugated to its target proteins by an elaborate enzymatic reac-
tion chain, which consists of an activating enzyme E1, a
conjugating enzyme E2, and a ligating enzyme E3 [6]. The
human genome encodes one E1, dozens of E2, and hundreds
of E3. Besides, the Ub chain can be cleaved from its target pro-
teins by deubiquitinating enzymes (DUBs), suggesting that
ubiquitination is reversible [7]. A target protein is modiﬁed
covalently with a single moiety of Ub (monoubiquitination)
through its C-terminal glycine (Gly) residue and a lysine
(Lys, K) residue within the target protein, or subsequently with
multiple moieties of Ub through its C-terminal Gly residue and
a Lys residue or the 1st methionine (Met) residue within the
pre-added Ub moiety. There are seven Lys residues (K6,
K11, K27, K29, K33, K48, and K63) and the initial Met resi-
due in the Ub polypeptide. Thus, there are at least 8 different
linkage types for polyubiquitination chains. Yet, a polyubiqui-
tination chain could be a mixture of more than one linkage
type, making this modiﬁcation more complex and divergent.
Different linkage types of ubiquitination modiﬁcation confer
a target with different biological functions [8]. Among them,
it is well known that the K48-linked poly-ubiquitination mod-
iﬁcation targets proteins for degradation through the 26S pro-
teasome, while the K63 linkage poly-ubiquitination regulates
protein activity and protein–protein interaction networks
[9,10].
A number of small Ub-like proteins (UBLs), such as small
Ub-like modiﬁer (SUMO) [11], neural precursor cell-expressed
and developmentally-downregulated 8 (NEDD8) [12], and
interferon-stimulated gene 15 (ISG15) [13], have been subse-
quently identiﬁed. Although most UBLs have no obvious
sequence identity to Ub, they all share a similar tertiary struc-
ture. Like Ub, these UBLs can be covalently conjugated to
their target proteins through a series of enzymatic reactions
analogous to ubiquitylation, endowing them with different
biological functions [14]. The UBLs are divided into two sub-
families. Type-1 UBLs, such as SUMO, NEDD8, and UCRP/
ISG15, are ligated to target proteins in a process similar to
ubiquitylation. Type-2 UBLs, which are also known as Ub
domain proteins (UDPs), have a similar structure to Ub and
are embedded in different large proteins [13]. These include
Rad23, elongin B, and parkin [14].
Ubiquitin fold modiﬁer 1 (UFM1) is one of the newly-
identiﬁed type 1 UBLs [15]. Like ubiquitination, UFM1 is con-
jugated to a target protein by a three-step enzymatic reaction
involving E1, the UFM1-activating enzyme (ubiquitin-like
modiﬁer-activating enzyme 5; UBA5); E2, the UFM1-
conjugating enzyme 1 (UFC1); and E3, the UFM1-speciﬁc
ligase 1 (UFL1). Usually, UFM1 is present in a precursor form
(Pro-UFM1). Cleavage by the UFM1-speciﬁc proteases
(UfSPs) exposes the conserved Gly residue on its C-terminus
and this residue is essential for its subsequent conjugating reac-
tions. Thereafter, with the help of ATP, the mature form of
UFM1 is activated by UBA5, forming a high energy thioester
bond with the Cystine (Cys) 250 of UBA5. Next, UFC1 inter-
acts with the Ub-fold domain of UBA5, and the activated
UFM1 is transferred to the UFC1, forming a similar thioester
linkage with Cys116 in UFC1. Finally, with the help of UFL1,
UFM1 is conjugated to its target proteins, such as UFM1-
binding protein 1 (UfBP1) [16] and activating signal cointegra-
tor 1 (ASC1) [17] (Figure 1). The speciﬁc UfSPs can also cleaveUFM1 from its target proteins, suggesting that ufmylation is
reversible [18,19] (Figure 1). UFM1 cascade is conserved
among nearly all the eukaryotic organisms, except yeast
[18,20], implying the essential role of UFM1 modiﬁcation in
cellular activities. Recent studies have uncovered that UFM1
modiﬁcation is tightly related to the endoplasmic reticulum
(ER) stress [21,22], hematopoiesis [23–25], fatty acid metabo-
lism [26], and G-protein coupled receptor (GPCR) biogenesis
[27]. Furthermore, the abnormal UFM1 cascade is reported
to be associated with a number of human diseases, including
cancer, ischemic heart diseases, diabetes, atherosclerosis, hip
dysplasia, and schizophrenia [17,18].
The human genome encodes a single ufmylation cascade
(UBA5UFC1UFL1); however, its physiological substrates
are far from clear. In this review, we will introduce the human
ufmylation cascade, its known physiological substrates, and its
involvement in a few cellular activities. We will summarize the
abnormalities of the ufmylation cascade in different tumors. A
perspective of ufmylation in tumorigenesis and cancer therapy
will be discussed as well.Key players of the ufmylation process
Key players of the ufmylation process include UFM1, UBA5,
UFC1, UFL1, and UfSP2 [18].
UFM1, also known as C13orf20, consists of 85 AA residues
with a calculated molecular mass of 9.1 kDa. Although human
UFM1 only has 16% sequence identity with Ub, the global
fold of human UFM1 is similar to that of Ub in their tertiary
structures [15]. While Ub and many UBLs have the conserved
C-terminal di-Gly (Gly-Gly) residues, the mature UFM1 only
has a single Gly residue at its C-terminus followed by a
Ser-Cys dipeptide. Present in a precursor form in human cells,
UFM1 is processed by the two UfSPs, namely, UfSP1 and
UfSP2, to produce mature UFM1 [19]. Immunocytochemical
analysis revealed that UFM1 is localized both in the nucleus
and the cytoplasm [15]. UFM1 is conserved in metazoan and
plants, but not found in yeast, suggesting its speciﬁc roles in
multicellular organisms.
UBA5, also known as UBE1DC1, is the only E1 enzyme for
ufmylation encoded by the human genome [15,28]. UBA5
encodes a polypeptide of 404 AA residues with a calculated
molecular weight of 44.7 kDa. Typically, a Ub-activating
enzyme E1 comprises the ﬁrst and second catalytic cysteine
half-domains (FCCH and SCCH, respectively), adenylation
domain, and C-terminal Ub-fold domain [29]. However,
UBA5 does not possess all these characteristic domains;
instead, it only has an adenylation domain where the catalytic
Cys250 is located and a Ub-fold domain [30]. Thus, UBA5 is
signiﬁcantly smaller than other Ub-associated (UBA) family
members. UBA5 is mainly detected in the cytoplasm. Interest-
ingly, a typical E1 works as a dimer to activate its speciﬁc
Ub-like proteins. While the monomeric UBA5 is able to
activate UFM1 in vitro [15,30], whether UBA5 works as a
dimer or monomer in vivo is awaiting further investigation.
A canonical E1 activates a UBL through a three-step mech-
anism. In the ﬁrst step, E1 binds ATP and UBL, forming a
UBL-adenylate intermediate. Second, the conserved Cys resi-
due in the catalytic cysteine domain reacts with the UBL-
adenylate to form an E1-UBL thioester. Third, the E1-UBL
thioester catalyzes another round of UBL adenylation with
UBA5
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UBA5 UBA5
UFL1
Subs
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Figure 1 The human ufmylation pathway
Pro-UFM1 is cleaved by the UfSPs to expose its C-terminal conserved Gly residue. The mature form of UFM1 is activated by UBA5 at
the expense of ATP hydrolysis, forming a high energy thioester bond with Cys 250 of UBA5. The E2 UFC1 then binds to UBA5, and the
activated UFM1 is transferred to UFC1, forming a similar thioester linkage with Cys116 in UFC1. Finally, the E3 ligase UFL1 brings in a
substrate (Subs) and UFC1-activated UFM1, UFM1 is then conjugated to its substrate. For the reverse process, UfSP2 cleaves UFM1
chains from its substrate. UFM1, ubiquitin-fold modiﬁer 1; Pro-UFM1, UFM1 precursor; UfSP, UFM1-speciﬁc protease; UBA5,
ubiquitin-like modiﬁer-activating enzyme 5; UFC1, UFM1-conjugating enzyme 1; UFL1, UFM1-speciﬁc ligase 1.
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tion of UFM1 by UBA5 is via a two-step mechanism. First,
mature UFM1 forms a noncovalent complex with UBA5.
Then, with the help of ATP, UFM1 is conjugated to UBA5
at Cys250 in the catalytic domain via a thioester bond, forming
a binary complex [30]. It has been demonstrated that UBA5 is
speciﬁc for UFM1 activation [23], although there is a report
showing that UBA5 activates SUMO2 in the nucleus [31].
Signiﬁcantly, Uba5 knockout mice die in utero due to severe
anemia resulting from defective development in the megakary-
ocyte and erythroid progenitors [23]. The anemia phenotype
of the Uba5-deﬁcient mouse embryos can be rescued by trans-
genic expression of Uba5 in the erythroid lineage, together with
prolonged survival, although Uba5 is dispensable for the ery-
thropoietin production. These results reveal the important role
of the ufmylation process in erythroid differentiation [23].
UFC1, also known as HSPC155, consists of 167 AA resi-
dues with a calculated molecular weight of 19.4 kDa. UFC1
is predominantly localized in the nucleus and partially in the
cytoplasm [15]. Despite lacking obvious sequence homology
with other E2 enzymes, UFC1 does have a relatively conserved
catalytic core domain, which is conserved in all E2 enzymes
[15]. In the catalytic core domain, there are approximately 10
AA residues surrounding the active site Cys116, forming a
ﬂexible loop that is highly solvent-accessible. Once UFC1
binds to the C-terminal domain of UBA5, the activated
UFM1 is transferred to the Cys116 of UFC1 by a
trans-esteriﬁcation reaction [18,20].
The neuronal cell adhesion molecule (NCAM) plays impor-
tant roles in the neurodevelopment and in synaptic plasticity inthe adult brain [32]. NCAM140, an isoform of NCAM, was
shown to interact with UFC1 through its cytoplasmic domain
and co-localize with UFC1 on the surface of B35 neuroblas-
toma cells [32]. Besides, overexpression of UFM1 resulted in
the increased NCAM140 endocytosis [32]. Therefore, the
UFM1 cascade may play an essential role in trafﬁcking of cell
surface molecules.
UFL1, also known as Maxer, regulator of C53/LZAP and
DDRGK1 (RCAD), novel LZAP-binding protein (NLBP),
and KIAA0776, consists of 794 AA residues with a calculated
molecular weight of 89.5 kDa. UFL1 is mainly located in the
endoplasmic ER [16]. It possesses a transmembrane domain
and a nuclear localization signal (NLS), which is functional
only when the transmembrane domain is deleted [16]. The
N-terminal region of UFL1 is highly conserved across different
species and is important for the transfer of UFM1 from UFC1
to its target proteins [16]. Surprisingly, UFL1 does not possess
any typical domains conserved in E3 ligases, such as the
homologous to the E6AP carboxyl terminus domain (HECT),
the really interesting new gene (RING) ﬁnger domain, or
U-box [15]. For instance, an active cysteine site for transthio-
lation reaction within N terminus is typically identiﬁed in
HECT type E3 ligases; however, UFL1 lacks this cysteine site
[16]. Thus, it is believed that UFL1 may be a scaffold type
E3-like RING ﬁnger E3 protein that can recruit E2 enzymes
and target proteins.
Recent investigations have demonstrated that Ufl1 knock-
out mice die in utero due to severe anemia [24]. Knocking
down of Ufl1 resulted in increased ER stress and unfolded
protein response (UPR) in bone marrow cells. Furthermore,
Wei Y and Xu X /Ufmylation in Life 143loss of UFL1 compromised autophagic degradation, while ele-
vating mitochondrial mass and reactive oxygen species, p53
activation, DNA damage response, and death of hemato-
poietic stem cells (HSCs). Thus, UFL1 is indispensable for
embryonic development, erythroid differentiation, and HSC
survival [24].
The processing of the C-terminal region of Pro-UFM1, as
well as releasing of UFM1 from its target proteins, is mediated
by two UfSPs, UfSP1 and UfSP2 [19]. Human UfSP1 consists
of 217 AA residues with a calculated molecular weight of
23.4 kDa, while human UfSP2 (C4orf20) consists of 469 AA
residues with a calculated molecular weight of 53.2 kDa.
UfSP2 differs from UfSP1 due to the presence of an extended
N-terminal domain, which has a unique structure and may
play a role in recognizing the speciﬁc substrate during the
deconjugation process [19]. UfSP2 is present in nearly all mul-
ticellular organisms, while UfSP1 is not found in plants and
nematodes and is usually expressed weaker than UfSP2 [19].
Although UfSP1 and UfSP2 have no obvious sequence homol-
ogy with the known Ub-like protein speciﬁc proteases (ULPs)
and DUBs, they exhibit typical features of cysteine proteases,
including possession of a conserved catalytic triad Cys-His-
Asp and sensitivity of catalytic inhibition by sulfhydryl-
blocking agents [19]. Thus, the UfSPs may constitute a new
subfamily of the cysteine protease.
UfSP2 may also play a role in the maturation of GPCRs
on the ER membrane in a UFM1-independent manner in
Caenorhabditis elegans. The odorant response abnormal pro-
tein (ODR-8; analogous to human UfSP2)-containing complex
in the ER promotes GPCR folding, maturation, and export
from ER [27]. ODR-8 is reported to have a distinct neuronal
expression proﬁle in C. elegans, while other UFM1 pathway
members are mainly expressed in the intestine [33]. Besides, a
mutation of UfSP2 was reported in a case of the Beukes famil-
ial hip dysplasia [34], suggesting that the deufmylation process
gets involved in human pathogenesis as well.
Key physiological substrates of ufmylation
The physiological targets of the UFM1 conjugation system
remain largely undeﬁned. Only a handful of ufmylation targets
have been identiﬁed so far, including UFM1-binding protein 1
(UfBP1) and activating signal cointegrator 1 (ASC1).
UfBP1, also known as C20orf116, Dashurin, or DDRGK
domain containing 1 (DDRGK1), consists of 314 AA residues
with a calculated molecular weight of 35.6 kDa. UfBP1 is the
ﬁrst identiﬁed substrate of ufmylation [16]. UfBP1 contains a
transmembrane helix (AA residues 4–21), a NLS sequence
(AA residues 64–68), a proteasome-COP9-initiation factor
(PCI) domain (AA residues 228–272), and a DDRGK domain
(AA residues 253–267). The ufmylation of UfBP1 takes place at
the K267 in the PCI domain [16]. The PCI domain is best-
known for its role in mediating protein–protein interaction
and in the formation of several multiprotein complexes, such
as the 26S proteasome, the COP9 signalosome (CSN), and
the eukaryotic translation initiation factor 3 (eIF3) complex
[35]. UfBP1 is predominantly localized in the ER, and its
N-terminal signal domain is important for its localization in
the cytosolic side of the ER membrane. The ER-localized
UfBP1 can recruit UfSP2, and interact with UFL1 and C53
(also known as Cdk5rap3, one of the UFM1 substrates), toform a large multi-protein complex [16]. Defect in the N-
terminal signal sequence of UfBP1 results in nuclear localiza-
tion [16]. Overexpression of UfBP1 was associated with ER
proliferation and neogenesis [36], whereas knockout of UfBP1
caused an elevated ER stress and activation of UPR [25].
Moreover, UfBP1 can interact with UFM1 and UFL1, as
well as the substrates of ufmylation, such as ASC1 and C53,
forming a big complex. UfBP1 can promote the ufmylation
of ASC1 [17]. Consistent with this phenomenon, knockdown
of UfBP1 abolished the ufmylation of ASC1, and over-
expression of the UfBP1(K267R) mutant, which is deﬁcient
in the UfBP1 ufmylation, also abolished the ASC1 ufmylation
[17]. Germ-line deletion of UfBP1 resulted in defective ery-
throid development and embryonic lethality, while somatic
ablation of UfBP1 impaired adult hematopoiesis, leading to
pancytopenia and animal death [25]. Thus, UfBP1 is not only
a substrate of ufmylation, but the ufmylated UfBP1 may serve
as a cofactor for the ufmylation of other substrates.
ASC1 is a transcriptional coactivator of estrogen receptor-a
(ERa) as well as other nuclear receptors (e.g., C53, androgen
receptor, and thyroid hormone receptor) [37]. ASC1 possesses
a zinc ﬁnger (ZF) domain, which is thought to be a binding site
for nuclear receptors and transcriptional coactivators such as
p300 and steroid receptor coactivator1 (SRC1) [37]. Thus,
ASC1 may serve as a platform protein to recruit the necessary
components for nuclear receptor-mediated transcription.
Besides, ASC1 is thought to be a tumor suppressor, as it can
activate p53, induce apoptosis, and suppress NF-jB signaling
[17]. Knockdown of ASC1 reduced expression of erythroid
transcription factors, but did not elevate basal ER stress [25].
ASC1 is a novel UFM1 target protein [16]. It was recently
demonstrated that the polyufmylation of ASC1 promotes
breast cancer development [17]. The ASC1 ufmylation requires
all factors of the UFM1 cascade, including UFM1, UBA5
(E1), UFC1 (E2), UFL1 (E3), and UfBP1. Absence of any
of these factors will abrogate the ASC1 ufmylation. K324,
K325, K334, and K367 of ASC1 all serve as the acceptor sites
for UFM1 modiﬁcation, whereas only the K69 of UFM1 is
involved in the poly-UFM1 chain formation on ASC1 [17].
In the absence of estrogen, ASC1 in the ERa-positive breast
cancer cells undergoes polyufmylation, which is quickly
reversed by the bound UfSP2. In the presence of estrogen,
the ligand-bound dimeric ERa displaces UfSP2 from binding
to ASC1, allowing accumulation of ASC1 ufmylation.
Polyufmylated ASC1 may serve as a scaffold protein to recruit
p300, SRC1, and ASC1 itself to the promoter of ERa target
genes for transcriptional activation, thus leading to excessive
cell proliferation and ultimately tumor formation [38].
Key cellular processes regulated by ufmylation
Based on the physiological targets of ufmylation identiﬁed so
far, we have gained some insight of ufmylation in ER home-
ostasis, development and differentiation of blood progenitors.
In addition, the ufmylation may be involved in GPCR matura-
tion in C. elegans as mentioned above.
ER is an organelle essential for the protein processing, fold-
ing, and trafﬁcking, as well as lipid biosynthesis and calcium
homeostasis [39,40]. Thus, ER homeostasis is essential for pro-
tein maturation [39]. Disturbance of the ER homeostasis will
result in the ER stress response and the activation of UPR
144 Genomics Proteomics Bioinformatics 14 (2016) 140–146[39]. The UfBP1, UfSP2, UFL1, and UFM1 can form a large
protein complex at the cytosolic side of the ER membrane, and
the UFM1 modiﬁcation system was reported to play an impor-
tant role in the ER function [21,22].
The pathology of both type 2 diabetes and ischemic heart
disease is related to the ER stress response [21]. The expression
of UFM1 cascade is up-regulated in the pancreatic islets of
Langerhans and some other secretory tissues [21]. With the
treatment of glycosylation inhibitor tunicamycin (TM), or
ER Ca2+ ATPase inhibitor thapsigargin (TG) for ER stress
induction, increased expression of UFM1, UfBP1, and
UFL1 was observed in the mouse INS-1E cells [41]. When vesi-
cle trafﬁcking was inhibited by brefeldin A (BFA, an inhibitor
of vesicle trafﬁcking), the transcript levels of UFM1 system
increased, which was not observed in mouse embryonic ﬁbrob-
last cells (MEFs) with knocking down of X-box binding pro-
tein 1 (Xbp1), a transcription factor of UPR [22]. The
ufmylation-related genes all contain an XBP1-binding element
(UPRE) in their promoter regions [22]. Thus, the UFM1 sys-
tem may participate in vesicle trafﬁcking, loss of which will
lead to an increased protein load in the ER and subsequently
increase the ER stress [22].
It was reported that loss-of-function of ufmylation resulted
in an increased apoptosis of pancreatic beta cells [41]. Knock-
down of UFM1 increased the apoptosis of the mouse macro-
phage cell line RAW264.7 cells [42]. However, in C. elegans,
the UFM1 conjugation is high when the protein load is low
and vice versa [41]. Additionally, the UFM1 modiﬁcation can
also participate in other stress response, like oxidative, heat,
and pathogen stresses [43]. In Leishmania donovani, the
UFM1 cascade is located in the mitochondria, and can interact
with mitochondrial trifunctional protein (MTP) to affect the
beta oxidation of long-chain acyl-CoA esters [26,44]. Loss of
UFM1 results in the decreased amount of acyl-CoA and
reduces the survival of amastigotes in human macrophage cells
[26,44]. Thus, UFM1 modiﬁcation may play a protective role
in maintaining the ER homeostasis and avoid the ER stress-
induced apoptosis.
Germ-line deletion of Uba5, Ufl1, or Ufbp1 in mice all led
to embryonic lethality and impaired hematopoietic develop-
ment (erythroid linage development in particular) [23–25].
Additionally, Ufl1 knockout in mice compromised HSCTable 1 Abnormality of the ufmylation-related genes in different canc
Cancer type No. of cases UBA5 UFC1
Lung squamous cell carcinoma 178 11.8% (A) 7.3% (A
Lung adenocarcinoma 230 1.7% (A) 12.6%
Breast invasive carcinoma 974 0.9% (A) 13.6%
Ovarian serous cystadenocarcinoma 311 6.4% (A) 5.5% (A
Uterine corpus endometrioid carcinoma 240 1.3% (M) 5% (A)
Pancreatic adenocarcinoma 109 1.8% (D) 21.1%
Esophageal carcinoma 92 8.7% (A) 4.3% (A
Liver hepatocellular carcinoma 193 15.5%
Bladder urothelial carcinoma 127 1.6% (A) 18.9%
Sarcoma 256 0.4% (A) 6.6% (A
Lymphoid neoplasm diﬀuse large
B-cell lymphoma
48 4.2% (A) 4.2% (A
Prostate adenocarcinoma 420 1.7% (A) 1.2% (D
Note: Data were obtained from www.cbioportal.org in December 2015
ubiquitin-fold modiﬁer 1; UfSP, UFM1-speciﬁc protease; UBA5, ubiq
enzyme 1; UFL1, UFM1-speciﬁc ligase 1; A, ampliﬁcation; D, deletion; Msurvival, and tamoxifen-induced somatic knockout of Ufl1 in
mice resulted in death due to severe anemia [23–25]. Both
Ufl1 knockout and Ufbp1 knockout mice exhibited increased
ER stress and activation of UPR [24,25], further conﬁrming
ufmylation in ER homeostasis. It has been proposed that the
ufmylation pathway targets ASC1 for ufmylation, stimulates
expression of erythroid transcription factors, and thus ensures
erythroid development. In addition, the pathway also targets a
yet unknown factor for ufmylation, maintaining ER home-
ostasis, and thus promoting HSC survival [25].The ufmylation pathway in human diseases
Abnormalities in the ufmylation pathway have been found to
associate with varieties of human diseases, including ischemic
heart diseases [21], diabetes [21], atherosclerosis [42], hip dys-
plasia [34], schizophrenia [45], and cancer [17].
The ufmylation of ASC1 is important for the transactiva-
tion of ERa and thus breast cancer development [17]. In
addition, UfBP1 knockdown compromises cell proliferation and
invasion in human osteosarcoma U2OS cells [46]. However,
both UFL1 and UfBP1 have been reported to suppress the
NF-jB signaling pathway [46]. Thus, the ufmylation pathway
may promote or suppress tumorigenesis through targeting
different substrates. Indeed, in The Cancer Genome Atlas
(TCGA) cancer database (www.cbioportal.com), for lung
squamous cell carcinoma, lung adenocarcinoma, breast inva-
sive carcinoma, ovarian serous cystadenocarcinoma, uterine
corpus endometrioid carcinoma, esophageal carcinoma, liver
hepatocellular carcinoma, bladder urothelial carcinoma, and
sarcoma, at least one of the genes encoding the ufmylation fac-
tors (UBA5, UFC1, and UFL1) were ampliﬁed, while the gene
encoding UfSP2, the only known deufmylation factor, some-
times was deleted, in more than 3% of patient cases (Table 1).
However, despite the ampliﬁcation of UFC1 in pancreatic ade-
nocarcinoma and ampliﬁcation of both UFC1 and UFL1 in
diffuse large B-cell lymphoma, high percentage of UFL1 dele-
tion and UFL1/UFM1 deletion was also detected in pancreatic
adenocarcinoma and diffuse large B-cell lymphoma, respec-
tively (Table 1). It is of note that high percentage of UFL1/
UFM1 deletion was detected in prostate adenocarcinoma asers
UFL1 UfSP2 UFM1
) 1.7% (M), 1.7% (D) 5.6% (D) 1.1% (D)
(A) 0.9% (M), 0.9% (D) 2.6% (D) 0.4% (A),1.3 (D)
(A) 1.1% (A) 1.8% (D) 1.7% (D), 0.3% (A)
) 1% (A) 3.2% (D) 1% (D), 0.6% (A), 0.3% (M)
3.8% (M) 4.6% (M) 0.4% (D)
(A) 7.3% (D) 4.6% (D) 1.8% (D), 1.8% (A)
) 1.1% (D) 2.2% (A) 1.1% (D)
(A) 1.6% (D) 3.6% (D) 0.5% (D), 0.5% (A), 0.5% (M)
(A) 1.6% (M), 1.6% (D) 2.4% (M) 2.4% (D), 1.6% (A), 0.8% (M)
) 1.2% (A) 3.9% (D) 1.6% (A), 1.6% (D)
) 14.6% (D) 8.3% (D) 4.2% (D), 2.1% (A)
) 12.9% (D) 0.2% (D) 11.9% (D)
. Alterations with frequency >3% are highlighted in bold. UFM1,
uitin-like modiﬁer-activating enzyme 5; UFC1, UFM1-conjugating
, mutation.
Wei Y and Xu X /Ufmylation in Life 145well (Table 1). These molecular epidemiological datasets fur-
ther support the observation that the ufmylation process
may have opposite effects on tumorigenesis. Given that only
one E3 for ufmylation has been identiﬁed so far, we believe
that more E3 ligases await exploration.
Conclusions
The UFM1 modiﬁcation is a brand-new and very attractive
Ub-like modiﬁcation. With the very limited knowledge of
ufmylation targets, we are far from appreciation of its
molecular impact on cellular activities and etiology of human
diseases, as well as its implication as therapeutic targets.
We are very keen to understand (1) what the additional E3
ligases for ufmylation are; (2) what the additional ufmylation
substrates are; (3) in addition to ER stress response and
hematopoietic development, what other cellular activities
the reversible ufmylation pathway regulates; (4) what the
molecular mechanisms of the opposite effects on tumorigen-
esis are; (5) which ufmylation factor(s) is (are) an ideal
biomarker and therapeutic target for certain types of cancer.
Hence, the sleeping beauty of ufmylation is waiting for the
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